High Dose LX2006 + Low dose LX2006 + Mid Dose LX2006 for cardiomyopathies

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jul 2022: Trial registered, NCT05445323
  2. 24 Aug 2022: Trial started, NCT05445323

The trials

NCT05445323: Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

State
Under way
Phase
Phase 1 and Phase 2
People
8 taking part
Started
24 Aug 2022
Primary completion
Sep 2029
Arms
Cohort 1/ Cohort 2/ Cohort 3
Results
None posted
  1. 6 Jul 2022: Trial registered
  2. 24 Aug 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.